Analytical Data
-
Gene name
HMGB1
- Application
-
Alternative Names
HMGB1;HMG1;High mobility group Protein B1
-
Species
Human
-
Source
HEK293 cells
-
Tag
C-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P09429
-
Molecular Weight
28 kDa as determined by SDS-PAGE reducing conditions
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
-
Immobilized Recombinant human HMGB1 at 2 μg/mL (100 μL/well) can bind Recombinant human AGER with a linear range of 1-45 ng/mL.The EC50 is 70ng/mL.
-
Immobilized Recombinant human HMGB1 at 2 μg/mL (100 μL/well) can bind Recombinant human AGER with a linear range of 1-45 ng/mL.The EC50 is 70ng/mL.
-
Recombinant Human HMGB1 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 28 kDa.
Protein Description
High-mobility group box 1 (HMGB1) is a highly conserved nuclear protein that plays a crucial role in cellular processes such as DNA repair, gene expression, and chromatin remodeling. It is also recognized as an important extracellular signaling molecule involved in inflammation and immune responses. Research has indicated that HMGB1 can act as a pro-inflammatory cytokine when released from damaged or infected cells, contributing to various pathological conditions including autoimmune diseases, sepsis, and cancer. Due to its significant role in these processes, HMGB1 has emerged as a potential therapeutic target. The production of recombinant HMGB1 protein allows for detailed studies of its biological functions, mechanisms of action, and interactions with other proteins and receptors. These studies are essential for understanding its dual roles in the nucleus and extracellular environment, as well as for developing HMGB1-based biomarkers and therapeutic interventions. The investigation of HMGB1 at the protein level enables researchers to explore its post-translational modifications, binding properties, and effects on cellular signaling pathways, thus providing insights into its involvement in various diseases and the potential for novel treatment strategies. Overall, the study of recombinant HMGB1 protein holds promise for elucidating its multifaceted role in health and disease, paving the way for future clinical applications and the development of HMGB1-targeted therapies.
